Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nykode Enters New Phase With Regeneron Vaccine Pact

US Major Pays $30m Upfront And Takes Stake

Executive Summary

Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.

You may also be interested in...



Deal Watch: Lilly Teams With Regor On Metabolic Disorders

Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.

France's Abivax Looks A Likely M&A Target

With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.

Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets

Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel